Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

PR Newswire 1 day ago

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire 12 days ago

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

PR Newswire November 6, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

PR Newswire October 8, 2024

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire September 5, 2024

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

PR Newswire August 19, 2024

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 14, 2024

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

PR Newswire August 5, 2024

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire May 20, 2024

Talphera to Participate at A.G.P. Virtual Healthcare Conference

PR Newswire May 16, 2024

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 14, 2024

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

PR Newswire May 2, 2024

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire March 6, 2024

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

PR Newswire March 1, 2024

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

PR Newswire February 26, 2024

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

PR Newswire January 18, 2024

AcelRx Announces Rebranding With Name Change to Talphera, Inc.

PR Newswire January 9, 2024

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States

PR Newswire December 12, 2023

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 8, 2023

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad(TM) Clinical Study

PR Newswire November 7, 2023